【2025 ESMO Asia 搶先看】🏥 緊追醫療科技最前線

0:00 開始
0:08 晚期三陰性乳一線治療的重大突破, 最新ADC藥物
1:06 細胞治療實體腫瘤治療革命！除了CAR-T，還有TIL、TCR？胃癌新標靶CLDN18.2是什麼？ ！
2:29 被稱為「癌王」的胰臟癌, 深入剖析兩大核心基因突變：KRAS 與 BRCA，迎來革命性的標靶治療曙光！
3:55 肺癌五大重要的可標靶基因？ALK、ROS1、HER2、MET、KRAS
6:02 鼻咽癌，治療有更強武器雙靶點ADC？

6️⃣在2025年ESMO大會上發表的TROPION-Breast02 III期研究結果顯示，針對TROP2的ADC藥(抗體藥物偶聯物) Dato-DXd為不適合PD1免疫治療的晚期三陰性乳病人者帶來了一線治療的重大突破。數據支持Dato-DXd成為該類病人新的標準第一線治療方案

7️⃣ 你是否以為細胞治療只對血癌有效？這場抗癌戰役的最新前線，已經瞄準了肺癌、肝癌、乳癌等「實體腫瘤」！這段將深入淺出，帶你認識三大尖端免疫細胞療法：

🧬 TILs (腫瘤浸潤淋巴細胞)：從患者腫瘤中直接提取「最強士兵」淋巴細胞，擴增數十億後回輸，讓免疫大軍直攻癌細胞堡壘。
🔗 TCR-T (T細胞受體工程化T細胞)：如同為T細胞安裝「精準雷達」，讓它能識別腫瘤細胞內部的隱藏標靶，進行深度打擊。
🎯 CAR-T (嵌合抗原受體T細胞)：為T細胞裝上「導彈發射器」，使其能直接鎖定癌細胞表面的特定受體

8️⃣被稱為「癌王」的胰臟癌的基因突變有什麼? KRAS 與 BRCA
🧬 · 超過 90% 的胰腺癌帶有 KRAS 基因突變, 命令細胞「生長、分裂」，導致癌症失控。
· 現在突破：全新一代的 KRAS G12C 抑制劑 已成功問世，能像一把「特製鑰匙」精準鎖定特定突變，關閉生長訊號。針對胰腺癌更常見的 KRAS G12D 等其他突變，多款新藥也正在臨床試驗中，前景可期！

🧬 BRCA 突變 — DNA 修復的「缺陷」
· 一部份胰腺癌患者（尤其有家族史者）帶有 BRCA1/2 基因突變。
· 使用 PARP 抑制劑 進行「合成致死」療法

9️⃣ 肺癌治療已進入「精準醫療」時代。將詳細解析肺癌中五大重要的可標靶基因：ALK、ROS1、HER2、MET、KRAS，並盤點對應的標靶藥物

🔟鼻咽癌新希望？全球首創雙靶點ADC新藥iza-bren最新療效數據解析

👇 歡迎在留言區分享你的想法或疑問！
🔔訂閱頻道，緊追醫療科技最前線！
#細胞治療 #實體腫瘤 #CART #TIL #TCR #免疫療法 #胃癌 #Claudin182 #癌症治療 #醫療科普 #esmoasia #esmoasia2025 #醫學會議

0:00 Start
0:08 A major breakthrough in first-line treatment of advanced triple-negative breast cancer: the latest ADC drug
1:06 A revolution in solid tumor treatment with cell therapy! Besides CAR-T, what about TIL and TCR? What is the new target for gastric cancer, CLDN18.2?!
2:29 Pancreatic Cancer, Known as the “King of Cancers”: In-depth analysis of the two core gene mutations : KRAS and BRCA, and explanation to a revolutionary glimmer of targeted therapy!
3:55 Lung cancer treatment has entered the era of “precision medicine.” This article will provide a detailed analysis of five important targetable genes in lung cancer: ALK, ROS1, HER2, MET, and KRAS, and review the corresponding targeted drugs.
6:02 New hope for nasopharyngeal carcinoma? Analysis of the latest efficacy data for the world’s first dual-target ADC drug, iza-bren.

6️⃣Presented at ESMO 2025,the Phase III TROPION-Breast02 trial demonstrated that the TROP2-directed antibody-drug conjugate Dato-DXd is a breakthrough first-line treatment for patients with metastatic triple-negative breast cancer ineligible for immunotherapy. This landmark study supports Dato-DXd as a new standard of care in this first-line setting, shifting a treatment paradigm long dominated by chemotherapy alone.

7️⃣| The Cell Therapy Revolution in Solid Tumors: Beyond CAR-T to TIL, TCR & the Stomach Cancer Breakthrough)
Is cell therapy only for blood cancers? The latest frontier in the fight against cancer is targeting solid tumors like lung, liver, and breast cancer! In this video, we break down the three most advanced immune cell therapies:

🧬 TILs (Tumor-Infiltrating Lymphocytes): Harvesting the “elite soldiers” (lymphocytes) directly from the patient’s tumor, expanding them billions of times, and reinfusing them to attack the cancer fortress.

🔗 TCR-T (T Cell Receptor-Engineered T Cells): Equipping T cells with a “precision radar” to recognize hidden targets inside tumor cells for a deep strike.

🎯 CAR-T (Chimeric Antigen Receptor T Cells): Arming T cells with a “missile launcher” to directly lock onto specific markers on the cancer cell surface. This is the hottest field right now!

8️⃣ Pancreatic cancer, often called the “king of cancers,” There are two potential genetic mutations KRAS and BRCA mutations

🧬 · Over 90% of pancreatic cancers harbor a KRAS gene mutation.
· It orders cells to “grow and divide,” leading to uncontrolled cancer.
· The Breakthrough Now: A new generation of KRAS G12C inhibitors has successfully emerged. They work like a “custom-made key” that precisely locks onto the specific mutation, turning off the growth signal. For other common KRAS mutations in pancreatic cancer like G12D, multiple promising drugs are in clinical trials, offering significant hope for the future!

🧬 The BRCA Mutation — A “Defect” in DNA Repair
· A subset of pancreatic cancer patients (especially those with a family history) carry inherited or acquired BRCA1 or BRCA2 gene mutations.
· Using PARP inhibitors pushing the already vulnerable cancer cells over the edge to death, while sparing healthy cells.

9️⃣The treatment of lung cancer has entered the era of “precision medicine.” The first crucial step is to identify the specific “driver gene” that fuels cancer growth through genetic testing. This episode delves into five key actionable genes in lung cancer — ALK, ROS1, HER2, MET, and KRAS — and reviews their corresponding targeted therapies

🔟New Hope for NPC? Latest Efficacy Data on the First-in-Class Bispecific ADC Drug Iza-bren

👇 Share your thoughts or questions in the comments below!
🔔Subscribe to stay on the cutting edge of medical technology!
#CellTherapy #SolidTumors #CAR-T #TIL #TCR #Immunotherapy #GastricCancer #StomachCancer #Claudin182 #CancerTreatment #ScienceCommunication